BACKGROUND AND OBJECTIVES: The relationship between aspirin use and arteriovenous fistula (AVF) survival has been lacking. The aim of this study was to evaluate the association between AVF survival and aspirin use. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 2815 incident hemodialysis patients (on dialysis <or= 30 d) using an AVF at enrollment into the Dialysis Outcomes and Practice Patterns Study between 1996 and 2004 were analyzed. Cox regression was used to examine the association between aspirin use and the risk of final AVF failure, first AVF failure, and a gastrointestinal bleeding event. Aspirin use was determined at baseline and one year later. Patients using aspirin at baseline and one year later were considered consistent aspirin users. All models accounted for facility clustering effects and were adjusted for age, race, gender, body mass index, prior permanent access failure, prior placement of a catheter, 10 comorbid conditions, laboratory data, and other medications, and stratified by regions. RESULTS: Consistent aspirin use was significantly related to a lower risk of final AVF failure. Facility-level analysis, which may reduce confounding by indication, also showed a nearly significant trend of reduced risk of final AVF failure with greater prevalence of consistent aspirin use within dialysis facilities (P for trend = 0.07). The occurrence of a new gastrointestinal bleeding event during the study period was not associated with aspirin use. CONCLUSIONS: These results suggest that consistent aspirin use may be beneficial for AVF survival among incident hemodialysis patients.
BACKGROUND AND OBJECTIVES: The relationship between aspirin use and arteriovenous fistula (AVF) survival has been lacking. The aim of this study was to evaluate the association between AVF survival and aspirin use. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data on 2815 incident hemodialysis patients (on dialysis <or= 30 d) using an AVF at enrollment into the Dialysis Outcomes and Practice Patterns Study between 1996 and 2004 were analyzed. Cox regression was used to examine the association between aspirin use and the risk of final AVF failure, first AVF failure, and a gastrointestinal bleeding event. Aspirin use was determined at baseline and one year later. Patients using aspirin at baseline and one year later were considered consistent aspirin users. All models accounted for facility clustering effects and were adjusted for age, race, gender, body mass index, prior permanent access failure, prior placement of a catheter, 10 comorbid conditions, laboratory data, and other medications, and stratified by regions. RESULTS: Consistent aspirin use was significantly related to a lower risk of final AVF failure. Facility-level analysis, which may reduce confounding by indication, also showed a nearly significant trend of reduced risk of final AVF failure with greater prevalence of consistent aspirin use within dialysis facilities (P for trend = 0.07). The occurrence of a new gastrointestinal bleeding event during the study period was not associated with aspirin use. CONCLUSIONS: These results suggest that consistent aspirin use may be beneficial for AVF survival among incident hemodialysis patients.
Authors: Rajiv Saran; Dawn M Dykstra; Robert A Wolfe; Brenda Gillespie; Philip J Held; Eric W Young Journal: Am J Kidney Dis Date: 2002-12 Impact factor: 8.860
Authors: Ronald L Pisoni; Eric W Young; Dawn M Dykstra; Roger N Greenwood; Erwin Hecking; Brenda Gillespie; Robert A Wolfe; David A Goodkin; Philip J Held Journal: Kidney Int Date: 2002-01 Impact factor: 10.612
Authors: R Scott Wright; Guy S Reeder; Charles A Herzog; Robert C Albright; Brent A Williams; David L Dvorak; Wayne L Miller; Joseph G Murphy; Stephen L Kopecky; Allan S Jaffe Journal: Ann Intern Med Date: 2002-10-01 Impact factor: 25.391
Authors: Jean Ethier; Jennifer L Bragg-Gresham; Luis Piera; Tadao Akizawa; Yasushi Asano; Nancy Mason; Brenda W Gillespie; Eric W Young Journal: Am J Kidney Dis Date: 2007-10 Impact factor: 8.860
Authors: Andrea K Viecelli; Elaine Pascoe; Kevan R Polkinghorne; Carmel Hawley; Peta-Anne Paul-Brent; Sunil V Badve; Alan Cass; Stephane Heritier; Peter G Kerr; Trevor A Mori; Amanda Robertson; Hooi L Seong; Ashley B Irish Journal: BMC Nephrol Date: 2015-06-27 Impact factor: 2.388